跳至主要内容
临床试验/NCT05162391
NCT05162391已完成不适用

Effects of Methamphetamine Use on Risk Behavior, Systemic and Mucosal Inflammation, and Sexually Transmitted Infection (STI)/HIV Risk Among Men Who Have Sex With Men

University of California, Los Angeles2 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2022年5月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
59
试验地点
2
主要终点
Methamphetamine abstinence

研究概览

简要总结

This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Cisgender male
  • 18 years of age or older
  • Understand written and spoken English
  • Condomless receptive anal intercourse in past 90 days
  • Meet DSM-5 criteria for methamphetamine use disorder
  • Positive urine toxicology screen for MA metabolites at study entry
  • Negative rectal GC/CT screen (n=20) or Positive rectal GC and/or CT screen (n=20)
  • Able to provide written informed consent and willing/able to complete study visits.

排除标准

  • Reports current treatment for another substance use disorder
  • Positive test for opioids, cocaine, and/or hallucinogens
  • Treatment for gonorrhea and/or chlamydia infection in past 3 months
  • Presence of a condition that in the opinion of the investigator would compromise the safety of the patient or the quality of the data

研究组 & 干预措施

Contingency management

Other

All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.

干预措施: Contingency Management (Behavioral)

结局指标

主要结局

Methamphetamine abstinence

时间窗: 8 weeks

Proportion of visits in which there are no detectable methamphetamine metabolites in participant urine samples

Rectal inflammation

时间窗: 8 weeks

Rectal concentrations of IL-6 (pg/mL)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Cherie Blair, MD, PhD

Assistant Clinical Professor

University of California, Los Angeles

研究点 (2)

Loading locations...

相似试验

Inflammation in Methamphetamine and STIs (IMSTI) | 临床试验